Historical Valuation
AIM ImmunoTech Inc (AIM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -2.08. The fair price of AIM ImmunoTech Inc (AIM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.32 USD , AIM ImmunoTech Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.32
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AIM ImmunoTech Inc (AIM) has a current Price-to-Book (P/B) ratio of -0.54. Compared to its 3-year average P/B ratio of 1.54 , the current P/B ratio is approximately -135.04% higher. Relative to its 5-year average P/B ratio of 1.34, the current P/B ratio is about -140.27% higher. AIM ImmunoTech Inc (AIM) has a Forward Free Cash Flow (FCF) yield of approximately -380.71%. Compared to its 3-year average FCF yield of -128.62%, the current FCF yield is approximately 196.00% lower. Relative to its 5-year average FCF yield of -87.07% , the current FCF yield is about 337.25% lower.
P/B
Median3y
1.54
Median5y
1.34
FCF Yield
Median3y
-128.62
Median5y
-87.07
Competitors Valuation Multiple
AI Analysis for AIM
The average P/S ratio for AIM competitors is 0.07, providing a benchmark for relative valuation. AIM ImmunoTech Inc Corp (AIM.A) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -25.71%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AIM
1Y
3Y
5Y
Market capitalization of AIM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AIM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AIM currently overvalued or undervalued?
AIM ImmunoTech Inc (AIM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -2.08. The fair price of AIM ImmunoTech Inc (AIM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.32 USD , AIM ImmunoTech Inc is Undervalued By Fair .
What is AIM ImmunoTech Inc (AIM) fair value?
AIM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AIM ImmunoTech Inc (AIM) is between +Inf to +Inf according to relative valuation methord.
How does AIM's valuation metrics compare to the industry average?
The average P/S ratio for AIM's competitors is 0.07, providing a benchmark for relative valuation. AIM ImmunoTech Inc Corp (AIM) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -25.71%, this premium appears unsustainable.
What is the current P/B ratio for AIM ImmunoTech Inc (AIM) as of Jan 09 2026?
As of Jan 09 2026, AIM ImmunoTech Inc (AIM) has a P/B ratio of -0.54. This indicates that the market values AIM at -0.54 times its book value.
What is the current FCF Yield for AIM ImmunoTech Inc (AIM) as of Jan 09 2026?
As of Jan 09 2026, AIM ImmunoTech Inc (AIM) has a FCF Yield of -380.71%. This means that for every dollar of AIM ImmunoTech Inc’s market capitalization, the company generates -380.71 cents in free cash flow.
What is the current Forward P/E ratio for AIM ImmunoTech Inc (AIM) as of Jan 09 2026?
As of Jan 09 2026, AIM ImmunoTech Inc (AIM) has a Forward P/E ratio of -0.28. This means the market is willing to pay $-0.28 for every dollar of AIM ImmunoTech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AIM ImmunoTech Inc (AIM) as of Jan 09 2026?
As of Jan 09 2026, AIM ImmunoTech Inc (AIM) has a Forward P/S ratio of 0.00. This means the market is valuing AIM at $0.00 for every dollar of expected revenue over the next 12 months.